MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Blood-Brain Barrier Opening with Focused Ultrasound in Parkinson´s Disease with Cognitive Impairment: A Safety and Feasibility Study

    C. Gasca-Salas, J. Pineda-Pardo, B. Fernández-Rodríguez, R. Rodríguez-Rojas, F. Hernández, I. Obeso, M. del Álamo, P. Guida, D. Mata-Marin, R. Martínez-Fernández, C. Ordás-Bandera, G. Foffani, I. Rachmilevitch, J. Obeso (Móstoles, Spain)

    Objective: To evaluate the safety and feasibility of MR guided focused ultrasound (MRgFUS) blood-brain barrier (BBB) opening in the cortex or the striatum in Parkinson´s…
  • MDS Virtual Congress 2020

    Enhancement of executive functions but not memory by multidomain cognitive group training in Parkinson patients with mild cognitive impairment: A multicenter randomized controlled trial

    E. Kalbe, A.K Folkerts, A. Ophey, C. Eggers, S. Elben, K. Dimenshteyn, P. Sulzer, C. Schulte, N. Schmidt, C. Schlenstedt, D. Berg, K. Witt, L. Wojtecki, I. Liepelt-Scarfone (Cologne, Germany)

    Objective: To determine cognitive training (CT) effects in Parkinson’s disease (PD) patients with mild cognitive impairment (PD-MCI) on cognitive and non-cognitive outcomes compared to an…
  • MDS Virtual Congress 2020

    Baseline results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort

    T. Myers, R. Schneider, L. Omberg, E. Macklin, E. Baloga, P. Snyder, S. Duquette, K. Amodeo, C. Tarolli, J. Adams, C. Lungu, J. Gottesman, E. Kayson, E. Dorsey, L. Mangravite, T. Simuni, M. Schwarzschild (Boston, MA, USA)

    Objective: To describe the baseline characteristics of Parkinson’s disease (PD) clinical trial participants enrolled in a remote, long-term observational follow-up study. Background: Participation in clinical…
  • MDS Virtual Congress 2020

    Perspectives on care for late stage Parkinson’s disease

    K. Rosqvist, M. Kylberg, C. Löfqvist, A. Schrag, P. Odin, S. Iwarsson (Lund, Sweden)

    Objective: The aim of this study was to explore experiences of late stage Parkinson's disease (PD) patients' and their informal caregivers’ satisfaction with care and support,…
  • MDS Virtual Congress 2020

    Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

    C. Tanner, D. Chernick, A. Formella (San Francisco, CA, USA)

    Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…
  • MDS Virtual Congress 2020

    Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease

    S. Ahmed, V. Naidu (Kamrup, India)

    Objective: Parkinson's disease (PD) is a distressing neurodegenerative disorder effecting nearly 2-3% of the total population greater than 65 years old . Several mechanisms have…
  • MDS Virtual Congress 2020

    The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: A pilot study

    H.C Chang, Y.C Tsai, C.S Lu (Taoyuan City, Taiwan)

    Objective: We aimed to investigate the add-on effect of Lactobacillus plantarum PS128 (PS128) in patients with Parkinson’s disease (PD). Background: PS128 is a specific probiotic…
  • MDS Virtual Congress 2020

    Claims Data Analysis of Parkinson’s Disease Medication Utilization

    M. Frazer, C. Blauer-Peterson, R. Sasane, S. Arcona, Y. Fang, R. Halpern (Eden Prairie, MN, USA)

    Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…
  • MDS Virtual Congress 2020

    Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease

    M. Javidnia, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

    Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…
  • « Previous Page
  • 1
  • …
  • 147
  • 148
  • 149

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley